Omeros (OMER) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros (OMER) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 335.5% versus a gain of 52.5%. Over five years, OMER leads with a +147.3% price change compared with +24.8% for TYRA. Omeros is the larger company by market cap ($1.38 billion vs $1.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OMER | TYRA |
|---|---|---|
| Share price | $19.12 | $19.97 |
| Market cap | $1.38B | $1.37B |
| 1-day change | +1.97% | -2.06% |
| YTD return | +11.29% | -22.44% |
| 1-year return | +335.54% | +52.51% |
| 5-year return | +147.35% | +24.79% |
| P/E ratio (TTM) | 15.67 | — |
| Forward P/E | 15.54 | — |
| EPS (TTM) | $1.22 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.24 | $40.65 |
| 52-week low | $4.06 | $13.29 |
| Distance from 52-week high | -9.98% | -50.87% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +43.83% | +137.61% |
| Average volume | 1.74M | 857.13K |
| Shares outstanding | 72.39M | 68.76M |
| Employees | 175 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed TYRA by 283.0 percentage points over the past year.
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
OMER vs TYRA FAQ
Which is bigger, Omeros or Tyra Biosciences?
Omeros (OMER) is larger, with a market capitalization of $1.38B compared with $1.37B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, OMER or TYRA?
OMER returned +335.54% over the past 12 months, compared with +52.51% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are Omeros and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.